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Abstract
Human breast cancer cell proliferation involves a complex interaction between growth factors, steroid hormones and
peptide hormones. The interaction of growth factors, such as epidermal growth factor (EGF), with their receptors on breast
cancer cells can lead to the hydrolysis of phospholipids and release of fatty acid such as arachidonic acid, which can be
further metabolized by cyclooxygenase (COX) and lipoxygenase (LOX) pathways to produce prostaglandins. The high
concentration of prostaglandins has been associated with chronic inflammatory diseases and several types of human
cancers. This is due to the over expression COX, LOX and other inflammatory enzymes. Ten peptides were designed and
synthesized by solid phase peptide synthesis and analyzed in vitro for enzyme inhibition. Out of these peptides, YWCS had
shown significant inhibitory effects. The dissociation constant (KD) was determined by surface plasmon resonance (SPR)
analysis and was found to be 3.39610
28 M and 8.6610
28 M for YWCS and baicalein (positive control), respectively. The
kinetic constant Ki was 72.45610
27 M as determined by kinetic assay. The peptide significantly reduced the cell viability of
estrogen positive MCF-7 and estrogen negative MDA-MB-231 cell line with the half maximal concentration (IC50)o f7 5mM
and 400 mM, respectively. The peptide also induced 49.8% and 20.8% apoptosis in breast cancer cells MCF-7 and MDA-MB-
231, respectively. The YWCS was also found to be least hemolytic at a concentration of 358 mM. In vivo studies had shown
that the peptide significantly inhibits tumor growth in mice (p,0.017). This peptide can be used as a lead compound and
complement for ongoing efforts to develop differentiation therapies for breast cancer.
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Introduction
LOX plays an essential role in the biosynthesis of leukotrienes
(LTs). LTs are potent biological mediators in the pathophysiology
of inflammatory diseases and host defense reactions. These
properties imply a significant role for LTB4 in the pathogenesis
of inflammatory diseases such as asthma, atherosclerosis and
cancer [1–4]. The metabolism of arachidonic acid via COX or
LOX pathway generates eicosonoids which has been implicated in
the pathogenesis of a variety of human diseases, including cancer,
and may play important roles in tumor promotion, progression
and metastasis. The involvement of LOX-12 expression and
function in tumor growth and metastasis has been reported in both
murine and human tumor cell lines [5]. LOX-12, product 12-
HETE is one of the most important lipid metabolites to influence
tumor progression [6]. It has been reported that LOX-12 is over
expressed in tumor tissues including prostrate, breast, colorectal
and lung cancer [7–10]. The tumor suppressive and anti-
angiogenesis effects of LOX-12 inhibitors may provide a new
approach to the treatment of human breast cancer. The
development of peptides as drugs is increasingly attracting the
attention of pharmaceutical companies. The advantages of
peptides as drugs include their high specificity, potency, and
activity. These peptides may be responsible for molecular
recognition and other biological processes. Small peptides as a
drug are very specific in nature. Also, peptide drugs pose other
advantages over therapeutic proteins, owing to their higher
solubility, better stability, more bio-availability and negligible
immune response. This study reports, in vitro and in vivo evaluation
of peptide inhibitors against human LOX-12.
Materials and Methods
Ethics Statement
The volunteers of the study provided written informed consent
and the Ethics Committee of All India Institute of Medical
Sciences (AIIMS) approved the study protocol and the permit
number is A-9/25.07.2007. The in vivo study was carried out in
strict accordance with the recommendations in the guide for the
care and use of laboratory animals of the AIIMS. The protocol
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32521was approved by the committee on the ethics of animal
experiments of AIIMS (Permit Number: 549/IAEC/10).
Cloning, expression, purification and characterization of
human LOX-12
The total RNA was isolated from MCF-7 cell line (National
centre for cell sciences, Pune, India) and converted to total cDNA
by using reverse transcriptase. The specific primer for human
LOX-12 was used for amplification and cloned into pGEMT easy
cloning vector (Promega) and subcloned in pET28a bacterial
expression vector. E. coli BL21 codon+ competant cells (Novagen)
were transformed with the expression vector containing His-
tagged LOX-12 using standard Novagen procedure. The cells
were grown at 310K in Luria-Bertani (LB) medium containing
50 mg/ml Kanamycin to an absorbance of 0.6 at 600 nm. The
expression was induced by the addition of 1 mM isopropyl-b-D-
thiogalactosidase (IPTG). The cells were grown for 4 h at 37uC
and centrifuged at 8,000 g for 10 min. The cell pellet was
resuspended in 10 ml of buffer (20 mM Tris-HCl pH–8.0,
150 mM NaCl). The cells were lysed by using sonicator(Sonics)
using 5 sec pulse On and 9 sec Off for 5 minute and centrifuged at
12,000 g for 20 min to remove the inclusion bodies. The protein
was purified from inclusion bodies under denaturing condition
using urea and refolded by passing through the column of Ni-
NTA-Agarose (5 ml, QIAGEN) equilibrated in binding buffer.
The bound protein was eluted with buffer containing 300 mM
imidazole. The protein was characterized by SDS-PAGE using
Laemmli system of buffers [11] and was then subjected to western
blotting. Gels were electroblotted (Protean Trans blot cells; Bio-
Rad) onto nitrocellulose membranes. The human LOX-12
primary antibody (1:500) and secondary antibody (anti-goat
alkaline phosphatase-conjugated; Santa Cruz Biotechnology, Inc)
were used for development of the blot.
Activity assay of Recombinant Human LOX-12
The activity of purified recombinant LOX-12 was determined
by using the conjugated diene method of biochemical assay.
Enzyme activity was indirectly measured by estimating the rate of
product formation. Hydroperoxy lipid product of the reaction
contains a conjugated diene which strongly absorbs at 234 nm.
The purified enzyme was used for activity assay. The assay
mixture contained 20 mM arachidonic acid (substrate), 0.2%
Tween-20, 50 mM potassium phosphate buffer pH 7.2 and
1.0 mM purified enzyme. The change in absorbance at 234 nm
was observed and the activity was calculated.
Synthesis of Peptides
The peptides were synthesized by solid phase peptide
synthesizer PS3 (Protein technology, USA) using Fmoc and Wang
resin chemistry [12]. The solvent used for the synthesis was
dimethylformamide (DMF). 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tet-
ramethyluronium hexafluorophosphate (HBTU) was used as an
activator of the Fmoc amino acids (Chem Impex, USA). Fmoc was
deprotected by 20% piperidine and wang resin was cleaved by
Trifluoroacetic acid (TFA). The peptides were precipitated from
dry ether.
Analytical RP-HPLC of Peptides
The purity of peptides was verified by analytical RP-HPLC,
C18 reversed phase column (RPC) (1.6610 cm, Amersham
Bioscience). 1 mg/mL of peptide was loaded to the RPC. The
linear gradients were formed by passing two different solvents,
where solvent A was 0.05% aqueous TFA, pH 2 and solvent B was
0.05% TFA in acetonitrile. The flow rate was 0.25 mL/min at
room temperature. The molecular weights were confirmed by
MALDI-TOF.
Kinetics and inhibition studies of the peptides by
spectrophotometer
For inhibition study, the human LOX-12 was incubated with
peptide for 30 min, which was then added to the reaction buffer
containing arachidonic acid (substrate), 0.2% Tween-20, 50 mM
potassium phosphate buffer pH 7.2. The change in absorbance
was monitored at 269 nm and the percentage of inhibition was
calculated. A control reaction was always carried out without any
peptide inhibitor to ensure the activity of protein under
experimental conditions.
For kinetic assay, the above experiment was done with four
different concentrations of peptides (25–100 mM). For each
concentration of peptide the experiment was repeated with six
different concentrations (20–120 mM) of substrate, arachidonic
acid. The enzyme concentration was constant (1.0 mM) through-
out the assay. The competitive kinetic constant (Ki) was calculated
graphically using the Michaelis-Menton equation in graphpad
prism software. The graph of activity vs. concentration of
arachidonic acid was plotted.
Binding studies of peptides with purified LOX-12 by SPR
The binding interaction between LOX-12 with peptides was
performed using a biosensor based on SPR. The interaction
phenomenon of two biological molecules can be monitored
directly by the SPR. The phenomenon of SPR was studied by
Otto [13] and Kretschmann and Raether [14] and it was used as a
chemical detection method by Nylander et al [15]. An automatic
instrument BIAcore 2000 (Pharmacia Bioscience) was used. Six
histidine-tag which were attached to the N-terminal position of
LOX-12 was an ideal tag for immobilization due to strong
rebinding effect caused by the high surface density of immobilized
Ni
2+–nitriloacetic acid (NTA) on the chips. The binding of analyte
i.e., the peptide in solution can be studied by monitoring the
change in the resonance unit (RU) values of the sensorgram, where
the progress of the interaction was plotted against time, revealing
the binding characteristics. Analysis of binding property i.e., the
association constant (KA) for the formation of multi-molecular
complex and dissociation constant (KD) were achieved in very
short time and with a small amount of samples. First the flow cell
was activated by passing nickel chloride and 60 ml of His-LOX-12
(50 mg/ml) was injected over the flow cell at the flow rate of 5 ml/
min. 350 RU of LOX-12 was immobilized under these conditions,
where 1 RU corresponds to immobilized protein concentration of
,1 pg/mm
2. The analyte i.e., peptide inhibitors at a concentra-
tion of 25 mM were passed over the immobilized LOX-12 at a
flow rate of 10 ml/min and the sensogram was run for 4 min,
likewise two more concentrations i.e, 50 and 75 mM of peptides of
same volume were passed over the chip and the change in
sensogram was observed. The graph shows the change in RU
values with time for different concentration of peptides. The rate
constants KA and KD were obtained by fitting the primary
sensorgram data using the BIA evaluation 3.0 software. The
dissociation rate constant is derived using equation:
Rt~Rt0e-kD(t-t0)
Where, Rt is the response at time t, Rto is the amplitudes of the
initial response and KD is the dissociation rate constant. The
association rate constant, KA can be derived using equation given
Identification of Novel Inhibitor for Human LOX-12
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Rt~Rmax½1{e{(KACzKD)(t{t0) 
Where, Rt is the response at time t, Rmax is the maximum
response, C is the concentration of the analyte in the solution.
Measurement of Minimal hemolytic concentration (MHC)
The effect of peptide on hemolysis was determined by using
human red blood cells (hRBC from volunteer). The freshly
collected hRBC were centrifuged for 10 mins to remove the buffy
coat and washed with phosphate buffered saline (PBS: 35 mM
Na2HPO4, pH 7.0 and 150 mM NaCl). 100 ml of the hRBC
(suspended in 1% (v/v) in PBS) and 10 ml peptide solution were
added into the sterile 96 well plates in triplicate. The plates were
incubated for 1 h at 37uC and centrifuged at 10006g for 5 mins.
The supernatant were transferred to fresh 96 well plates, where
hemoglobin released was monitored by measuring the absorbance
spectrophotometrically at 541 nm. Similar steps were carried out
for Gentamycin, as a control. The percentage of hemolysis
(determined in PBS and 0.1% Triton X-100) was calculated from
the standard graph which was plotted with % hemolysis of
prepared RBCs vs optical densities.
Tumor cell cytotoxicity of the inhibitory peptides by MTT
assay
Cytotoxic effect of LOX-12 inhibitory peptides was analyzed on
MCF-7 (ER+) and MDA-MB-231 (ER+) breast cancer cell lines by
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide] dye reduction assay. Briefly, 3610
3 cells/100 ml media were
seeded in 96-well plates 24 h before the experiment. The cells were
then incubated with different concentrations of the peptides for 24,
48 and 72 h as indicated. The cells were treated with DMSO (same
concentration as used to solubilise the peptide) which was then
subtracted from all the cytotoxic values.10 ml/well MTT-solution
(10 mg/ml in PBS) was then added and plates were further
incubated for 3 h at 37uC. The formazan crystals formed were
dissolved by adding 100 ml/well of dimethyl sulfoxide (DMSO).
Absorbance was measured by a microplate reader at 570 nm with a
reference filter 650 nm. 100 ml of medium with 10 mlo fM T T
stock-solution and 100 ml of DMSO was used as a blank solution to
correct the background. The data obtained was presented as
percentage viability in the best-fit (linear) dose response curve. The
IC50 values at 95% confidence intervals was calculated for all cell
lines. Each concentration was used in triplicate. The peptide AIRS
was used as a negative control. The MTT assay of peptide AIRS is
submitted as a supplementary data [Figure S1].
Assessment of apoptosis by annexin-V binding assay and
Flow Cytometry
The frequency of apoptosis in MCF7 cells and MDA-MB-231 by
the treatment with YWCS was assayed by annexin-V binding assay.
Briefly, MCF7 cells and MDA-MB-231 were pulsed with the
peptide for 72 h. After termination of the culture, cells were stained
with annexin-V apoptosis detection kit (Biolegend) according to the
manufacturer’s instructions. The cells were washed twice with PBS,
and resuspended in annexin-V binding buffer. To the cell
suspension, 5 ml of FITC-conjugated annexin-V (Biolegend) and
10 ml of propidium iodide (PI) (50 mg/ml) solution were added and
further incubated for 15 min at room temperature. About 10,000
events were acquired in FACS Canto flow cytometer (Becton–
Dickinson, USA). The frequency of annexin-positive (apoptotic)
cells was determined using BD FACSDiva software.
FITC labeling of peptides and their intracellular
localization
For labeling of peptides with Flourescein isothiocyanate (FITC),
1:1 equivalent of NH2-YWCS-wang resin and FITC in DMF were
stirred together overnight. The peptide labeled with FITC was
then cleaved from the resin using the standard procedure. To
evaluate the localization of the inhibitory peptide in MCF-7 and
MDA-MB231 cell line, cells were seeded on cover slips in 6-well
plates and allowed to adhere for 24 h. They were then treated with
the FITC-labeled peptide and incubated further for 48 h. The
cells were then washed with PBS, fixed with 4% paraformaldehyde
for 15 min and stained with 50 mg/ml PI for nuclear staining. The
cells were visualized under Confocal microscope (Nikon) for green
(FITC) and red (PI) fluorescence to check the intracellular
localization of the peptides.
Preliminary study of peptide action in tumor mice model
In-vivo animal experimentation of peptide for anticancer activity
was done using mice model. Swiss albino mice were obtained from
Central animal facility, AIIMS at 55–65 days of age. The animals
were housed in polycarbonated cages, bedded with husk. The
animal facility was environmentally controlled; mice were
maintained at normal room temperature with suitable relative
humidity and 12 h light, 12 h dark cycle. Animals were fed chow
food and purified water ad libitum throughout the study. Animals
were randomized into 5mice per cage in 3 groups (Group I, II and
III) for the study.
Tumor Induction
Ehrlich’s Ascites Tumor cell line (EAT) (murine breast
carcinoma), was used for tumor induction. The cell line was
maintained in-vivo by passaging weekly intraperitonealy (i.p) from
mice to mice. For tumor induction, 14 million cells approximately
150 ml volumes was injected to the animal in a group
subcutaneously on the dorsal side of the body (back) and kept
under observation for tumor onset.
Tumor size was recorded by vernier calipers and tumor volume
was calculated using the formula: V=0.56L6W
2, where L is the
length (long axis) and W is the width (short axis).
Evaluation of peptide action after injection in
experimental mice
In Group I (control, untreated) only tumor cell line was
administered. In group II, YWCS peptide was administered when
the tumor volume reached 0.2260.10 cm
3 on day 10, at a dose of
200 mmol intravenously (i.v) per mouse once daily for 20 days from
day 11 to day 30. In group III, same concentration of peptide was
injected intravenously (i.v) simultaneously after injecting tumor
cells subcutaneously on day one. During experimental period mice
were under observation till sacrificed.
Statistical analysis
The statistical analysis was carried out using the Graphpad
Instat 3 software and p,0.05 was considered statistically
significant. For the comparison of the findings, paired and
unpaired t-test was performed.
Results
Purification and Characterization of Human LOX-12
Human LOX-12 protein was purified from inclusion bodies by
the method of on-column refolding as described in the material
and methods section. Approximately 20 mg of protein was
Identification of Novel Inhibitor for Human LOX-12
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32521recovered from the Ni
2+-NTA affinity column. In SDS-PAGE
approximately 90–95% purity of the protein was observed (data
not shown). This was followed by western blotting showing the
presence of LOX-12 in the inclusion bodies of the bacterial cell
extract (Figure 1A).
Activity Assay of Human LOX-12
The activity of purified recombinant LOX-12 was determined
by using the conjugated diene method of biochemical assay.
Enzyme activity was indirectly measured by estimating the rate of
product formation. The graph (activity profile) of absorbance vs.
time is shown in Figure 1B.
Screening of peptides
The activity assay for LOX-12 in presence of 10 different
peptides with substrate was performed by using spectrophotom-
eter. The assay was performed at 269 nm which gives the
absorption maxima for the product LTB4. Table 1 shows the
percentage inhibition for the 10 peptides. The peptide YWCS
showed maximum inhibition of 80%.
Determination of kinetic constant (Ki)
Competitive kinetic constant of the best peptide YWCS was
calculated using graphpad prism software. A linearised analysis of
the data (Michaelis-Menten equation) [16] showed a competitive
mode of inhibition (Figure 1C). The Ki value obtained for the
peptide YWCS was 72.45610
27 M. The direct plots of reaction
velocity versus substrate concentration demonstrated classical
steady-state kinetic behavior.
Figure 1. Western blot showing LOX-12 expression: (A) Molecular weight marker, supernatant of bacterial extract, inclusion bodies
of bacterial cell extract, flow-through of the Ni-NTA column, purified refolded protein, (B) Activity profile of purified LOX-12. (C)
Michaelis-Menten plot of LOX-12 activity versus arachidonic acid concentration showing decrease in activity at different concentrations (0, 25, 50,




Table 1. The peptides screened as inhibitors of LOX-12.












Inhibition assays were performed in triplicates and average values have been
reported.
YWCS was found to be inhibit the activity of protein by 86.1%.
doi:10.1371/journal.pone.0032521.t001
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control.
doi:10.1371/journal.pone.0032521.g002
Figure 3. Dose-response curve: (A) showing % viability of MCF-7 cells at 0–150 mM concentrations of YWCS (0.05% DMSO as a
vehicle control), for three different time points (24, 48 and 72 h). IC50 was found to be 75 mMa t7 2h .(B) showing % viability of MDA-
MB-231 cells at 0–500 mM concentration of YWCS (0.05% DMSO as a vehicle control), for three different time points (24,48 and 72 h). IC50 was found
to be 400 mMa t7 2h .
doi:10.1371/journal.pone.0032521.g003
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The plot (Figure 1D) shows the sensorgram for the binding of
the varying concentrations of the peptide. The changes in RU with
varying concentration of peptide showed the change of mass on
the LOX-12 immobilized on chip with time. The binding of
peptide YWCS with LOX-12 was the strongest due to the faster
on (association), KA=2.95610
7 M was well as slower off rate
(dissociation) KD=3.39610
28 M.
Assay for hemagglutinating activity
The haemolytic activity of the peptide was determined to ensure
the toxicity to erythrocytes using human RBCs. The concentration
upto 358 mM of the peptide lysed only 22% human erythrocytes
(Figure 2).
Cytotoxic activity of peptides on breast cancer cell line
MCF-7 cells were treated with 0–150 mM( 0 . 0 5 %D M S Oa sa
vehicle control) and MDA-MB-231 was treated with 0–500 mM
(0.05% DMSO as a vehicle control) of the LOX-12 inhibitory
peptides for 24, 48 and 72 h to perform the cytotoxic activity.
The half maximal concentration (IC50)o f7 5mM was obtained
which represents the concentration of the peptide at which the
cell growth is inhibited by 50%. The percentage cells viability by
peptide at concentrations 25, 50, 100, 150 mM was 88.6, 85.7,
31.2, 21.1% respectively at 72 hrs. In case of MDA- MB 231,
the IC50 value was 400 mM .T h ep e r c e n t a g eo fc e l lv i a b i l i t y
after the treatment of peptide at concentrations 50, 100,
150,200,250,300,350,400 and 500 mM was 92, 87.46, 80.36,
72.51, 7.37,64.95, 54.76, 48.19, 43.07% respectively at 72 h.
The dose-response curves have been shown in Figure 3a
and 3b.
Apoptotic activity of YWCS on MCF-7 and MDA-MB-231
cells
The apoptotic activity of the peptide YWCS was performed
using annexin-V binding assay. Apoptosis induction was observed
as early as 72 h. In this experiment MCF-7 cells were treated with
50, 75 and 100 mM peptide YWCS (0.05% DMSO as a vehicle
control) and the mean percentage apoptotic cell were 41.265.8,
49.866.5 and 58.367.5, respectively, The mean percentage of
apoptotic cell were 15.061.2, 20.863.2 and 22.161.5 treated
with 350, 400 and 450 mM of peptide concentrations (0.05%
DMSO as a vehicle control) respectively in MDA-MB-231 cells,
The frequency of apoptotic cells was significantly higher in
peptide-treated cells; MCF-7 (p,0.0001) and MDA-MB231
(p,0.0010) compared to the untreated controls The frequency
Figure 4. Apoptotic analysis of cancer cells with YWCS by flow cytometry; MCF-7 cells: (A) untreated cells (0.05% DMSO as a vehicle
control),( B–D) treated with 50, 75 and 100 mM YWCS respectively,( E) treated with baicalein. MDA-MB231 cells :(F) untreated cells (0.05%
DMSO as a vehicle control), (G–I) treated with 350,400 and 450 mM YWCS respectively,(J) treated with baicalein. (K) and (L) bar diagram showing
mean percentage of apoptotic cells of the above cell lines treated and untreated with peptide and baicalein.[*** represent the comparison of bar of
treated cells with the untreated cells].
doi:10.1371/journal.pone.0032521.g004
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shown in Figure 4.
Intracellular localization of FITC labeled peptides
YWCS was tagged with FITC to observe its intracellular
localization in MCF-7 and MDA-MB-231 breast cancer cell lines.
The fluorescein-conjugated peptide was seems to be entered to
cytoplasmic regions of the cells. (Figure 5).
In vivo study: Efficacy of YWCS peptide for antitumoral
activity administrated on Swiss albino mice implanted
with EAT tumor cell line
During the period of study, there was no significant variation
in the weight of animals. The antitumor effect of YWCS peptide
administration on Swiss albino mice implanted with EAT tumor
cell line are shown in Table 2. All the control (untreated mice)
showed progressive increase in tumor volume, reaching
2.0960.06 cm
3 on day 20 to 4.560.24 cm
3 on day 30
(Fig. 6a). In contrast, the administration of YWCS peptide
200 mmol intravenously (i.v) once daily for 20 days from day 11
to day 30 in group II, the tumor volume reached
1.6260.49 cm
3 on day 20 and 3.0461.06 cm
3 on day 30
(Fig. 6a). A significant (p,0.017) difference was observed in the
tumor volume between group I and group II mice on day 20
and day 30 (Fig. 6a).
200 mmol of YWCS peptide was intravenously (i.v) adminis-
tered simultaneously after injecting EAT cell line at day one in
group III animals and kept them under observation for 20 days.
No tumor was observed in this group (Fig. 6b). A significant
variation was observed between group I and group III on day 20.
Group I (control) showed tumor initiation and progression both, in
contrast, group III (peptide treated) showed no tumor initiation.
In addition to this, Group I (control) and group II (peptide
treated for 20 days) showed liver and spleen enlargement in all the
sacrificed animals, but in group III, the size of liver and spleen was
similar to the healthy mice. Preliminary study of YWCS peptide
action showed that it could significantly suppress the growth of
tumor as well as prevented the initiation of tumor.
Figure 5. Confocal microscopy pictures showing localization of FITC-labelled YWCS in MCF-7 and MDA-MB-231 cells. White arrows in
the merged image show that the peptide enters the cell cytoplasm. (A) MCF-7 cells treated with 75 mM YWCS. (B) MDA-MB-231 cells treated with
400 mM YWCS peptide.
doi:10.1371/journal.pone.0032521.g005
Table 2. Antitumor activity on YWCS peptide on EAT tumor bearing mice.
Groups and treatment Tumor volume, cm
3
Day 10 Day 20 Day 30
Group I Control* (non treated) 0.04860.0009 2.0960.06 4.560.24
Group II YWCS peptide treated 200 mmol from day 11–30 0.2260.10 1.6260.49 3.0461.06
Group III EAT tumor cell line+peptide injected (i.v) No tumor onset No tumor onset No tumor
doi:10.1371/journal.pone.0032521.t002
Identification of Novel Inhibitor for Human LOX-12
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32521Discussion
There are three isoform of human LOX i.e; LOX-5, LOX-12
and LOX-15. It has been reported earlier that LOX-12 is over
expressed in breast cancer [9]. The structure of active site of 5, 12
and 15 LOX are similar. The inhibitor of LOX-5 like curcumin
and zileuton are anti-cancer agent [17–18]. Baicalein, which is the
specific inhibitor of LOX-12 showed anti cancer activity in
different cancer cell line [19]. Though the complex structure of
LOX-12 with inhibitor is not known, the available complex
structure with other LOX had shown that the presence of an
aromatic moiety with hydroxyl group and a hydrophobic residue
in the inhibitor are important for the affinity towards the active site
residue of LOX [20–21]. Earlier we have reported FWY as a
strong inhibitor of soybean LOX [22] In this study ten peptides
were screened for inhibition (Table 1).The first five peptides in
table 1 were reported in our previous paper [22] which had
already shown a good percentage of inhibition with soybean LOX-
3. So we carried out their inhibition test with human LOX-12.
The other five peptides were also designed keeping the two key
features in mind i.e; presence of an aromatic moiety with hydroxyl
group and hydrophobic residues which are important moieties for
the affinity to the active site of the protein.
The peptide YWCS showed highest affinity to LOX-12 among
the other peptides (Table 1). This peptide was confirmed to be a
competitive inhibitor in the presence of substrate. The binding
affinity of this peptide with LOX-12 was also confirmed by SPR
technology, where the dissociation constant was approximately in
nanomolar concentration range which was much higher than the
known inhibitors of LOX-12.
The LOX-12 metabolite, 12-HETE, has been reported to
increase the proliferation and invasion of breast cancer cells, by
mechanisms such as induction of collagenase secretion from the
cell [23]. This effects of LOX-12 can be blocked by inhibitors of
LOX-12 [24–25].
The association of breast cancer and estrogen receptor is very
well known. The breast cancer patients with ER+ have been
reported to have positive response to chemotherapy and good
prognosis [26–28]. Accordingly both the breast cancer cell line
MCF-7 (ER+) and MDA-MB-231 (ER2) were used to see the
effect of peptide on it. The peptide potentially inhibited the cell
growth of MCF-7 (ER+) and MDA-MB-231(ER2) in a dose and
time –dependent manner and also induced apoptosis in both the
breast cancer cell lines. Hence, cell death observed in breast
cancer cells treated with peptide inhibitor was via apoptosis
induction, which appear to be independent of the hormone
receptor status. The invasive breast cancer cell line MDA-MB231
expressed higher level of LOX-12 as compared to MCF7 [29].
The dose of peptide required for the cytotoxicity and apoptosis
was higher in case of MDA-MB231 compare to MCF-7. This
difference in dosage of peptide inhibitor of LOX-12 may be
assumed due to the difference in expression of LOX-12 in MDA-
MB231 and MCF-7 cell line. The exact reason yet to be
elucidated.
The appearance of permeabilized cells labeled with fluorescein-
conjugated peptide suggests that the peptide was internalized and
resided in the cytoplasmic region of the MCF-7 and MDA-
MB231cells. The peptide was proved to be specific inhibitor of
cystosolic enzyme LOX-12.
It was found that the peptide YWCS prevented the initiation of
tumor growth in mice when it was injected simultaneously with
tumor cell and it also slow down the tumor progression
significantly when the peptide dose was administered after 10
days of tumor growth. Thus we can speculate that LOX-12 under
in vivo conditions is more important for the progression of the
disease.
It can be summarized that the tetrapeptide designed on the basis
of the structure of LOX-12 is a potent inhibitor of LOX-12 and
can be a selective anti breast cancer agent due to its strong anti-
cancer property. The hemolytic studies showed that the peptide
was nearly non-toxic to human erythrocytes. This aspect of the
peptide showed that it can be delivered via the intravenous route,
although further evaluation is necessary.
Figure 6. In vivo experiments showing effect of YWCS on tumor initiation and progression: (A)- Group I; untreated mice, Group II;
treated mice with peptide after 20 days of treatment (treatment started after 10 days of tumor growth), Group III; peptide induce
simultaneously with EAT tumor cells showing no tumor initiation and (B)The tumor size of Group I and Group II mice after sacrifice.
doi:10.1371/journal.pone.0032521.g006
Identification of Novel Inhibitor for Human LOX-12
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32521In light of the above discussion we may state that YWCS can
surely set a platform for the development of a promising anti
cancer drug in future. This peptide can be use as a lead compound
and complement for ongoing efforts to develop differentiation
therapies for breast cancer.
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